Update your tester profile Login
  • Study 1400: Healthy, Sexually Active Male and Female Participants

    Research Purpose:  Study 1400

    The effect of the study drug on sexual functioning (i.e. frequency of sexual activity, thoughts, arousal, physical response etc.) when given to healthy sexually active adults.

    • The effect of the study drug compared to the effect of placebo and paroxetine (an FDA approved comparator drug) on sexual functioning

     

    Screening Qualifications: Participants must meet the following minimum criteria in order to qualify for a screening appointment:

    • Males and Females allowed. Age 18-45 years
    • Body Mass Index (BMI) between 18 and 35
    • No tobacco or nicotine use in the previous 12 months
    • Must be healthy; not being evaluated or treated for any medical conditions
    • Must not require regular use of prescription medications, non-prescription medications, or vitamins
    • Must test negative for drugs of abuse.  Must have no history of drug or alcohol abuse within the previous 5 years.
    • Must be sexually active:  engaging in sexual activity at least 2 times per week on average over the past 3 months.
    • Cannot have a diagnosis of disorders related to sexual functioning including but not limited to erectile dysfunction, premature ejaculation, or any surgeries or medical procedures on genital/reproductive organs
    • Must be able and willing to discuss sexual activity/functioning with Prism staff and fill out questionnaires related to sexual activity/functioning
    • Must be able and willing to take daily, at-home dosing of the study drug

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 6 weeks.  During that time, participants will visit Prism Clinical Research for approximately 7 outpatient appointments.  Participants will also take daily, at-home doses of the study drug and will keep an outpatient study diary.

     

    Compensation: Up to $1575.00 for study participation time.

  • Study 1405: Healthy Male and Female Participants

    Research Purpose:  Study 1405 is designed to evaluate the interaction of an investigational drug being developed for the treatment of human rhinovirus (cause of common cold) has on a FDA approved sedative, midazolam (Versed®).  the investigational drug will be given orally to healthy participants for seven consecutive days in the form of a capsule.  The total daily dose will be the same, but may be given either once or twice a day.  The FDA approved sedative will be given to participants orally, as a syrup. Participants will receive 4 total doses of the sedative. The following will be evaluated:

    • How the investigational drug impacts the blood levels of the FDA approved sedative
    • How midazolam (Versed®) impacts the blood levels of the investigational drug
    • the safety/tolerability of the investigational drug

     

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women are allowed to participate only if they are not pregnant or lactating

    Age

    18-55 years

    Body Mass Index (BMI)

    18 and 30

    Weight

    Must weigh greater or equal to 110 pounds

    Tobacco/Nicotine Use

    • Must not use of tobacco/nicotine products more than 5 times/day in the 90 days before the study. 
    • Must be able and willing to abstain from tobacco/nicotine use 14 days before the start of the study until the final study visit. 

    Drug Testing

    Must test negative for drugs of abuse. 

    Substance Abuse History

    No history of drug or alcohol abuse within 2 years before the start of the study

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

    Restricted Medications

    • No chronic use of any prescription medications not listed below in the 90 days prior to the start of the study through the final study visit
    • No over-the-counter medications, supplements, or vitamins 7 days prior to the start of the stud through the final study visit.

    Allowed Medications

    • Prescription hormonal birth control is allowed

     

    Study Time Commitment:

    For participants who qualify based on screening evaluation, study participation will last for approximately 16 days, beginning with the second study visit. 

     

    In-house Stays

    Participants will stay at Prism Clinical Research several times times. 

    • Three of the inpatient stays will last 1 and 1/2 days each
    • One of the inpatient stays will last 4 and 1/2 days

    Office Visits

    There will also be 4 brief morning visit for all participants, and on brief evening visit for participants dosing twice a day. 

     

    Compensation: For study participation time: Up to $2275.00 for once a day dosing; or $2350 for twice a day dosing.

  • Study 1401 Cohort 1: Healthy Male and Female Particpants

    Research Purpose: Study 1401 is designed to evaluate an investigational drug being developed for the treatment of pain management. Two pill formulations of the investigational drug will be given to healthy adults.  The following will be evaluated:

    • How much of the investigational drug gets into the blood when it’s given after eating food
    • How quickly the investigational drug gets into the blood and is eliminated from the body when it’s given after eating food
    • The safety/tolerability of the investigational drug

     

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate.

    Females

    Women are allowed to participate. 

    Age

    18-55 years

    Body Mass Index (BMI)

    17.5 and 30.5

    Weight

    Must weigh more than 110 pounds

    Tobacco/Nicotine Use

    Must be able and willing to abstain from tobacco or nicotine containing products during all inpatient stays

    Drug Testing

    Must test negative for drugs of abuse. 

    Alcohol/Drug Abuse History

    No history of drug or alcohol abuse

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

    Restricted Medications

    No required regular use of any prescription medications, non-prescription medications, or vitamins that are not listed below.

    Allowed Medications

    Prescription hormonal birth control use is permitted

    Dietary Requirements

    Must be able and willing to eat/drink the following: eggs, pork products, gluten, dairy, potatoes, and fruit (strawberries, grapes)

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 3 weeks. 

    Inpatient Stays

    • Participants will stay at Prism Clinical Research 3 times. 
    • Inpatient stays will last approximately 72 hours (three overnights

    Outpatient Visits

    • There are no scheduled outpatient visits in this study. 

     

    Compensation: Up to $2625.00

  • Study 1314-Participants with Type 2 Diabetes

    RESEARCH PURPOSE:  To study the safety, absorption, and elimination of a new investigational delayed release diabetes medication compared to an FDA approved version.  Also to determine how the medication affects the body in participants with Type 2 diabetes with normal kidney function and in participants with Type 2 diabetes and low kidney function.

     

    BASIC PARTICIPANT QUALIFICATIONS:

    • Men and Women with Type 2 Diabetes
    • Men and Women with Type 2 Diabetes and low kidney function
    • Aged 18-80 years old
    • BMI between 18--40
    • Stable and controlled medical conditions
    • All medicines will be reviewed before qualification is determined
    • Able and willing to eat/drink or avoid study specific foods/beverages

    STUDY LENGTH: One initial screening visit to determine eligibility.  A baseline overnight stay to confirm eligibility followed by 3 treatment periods each consisting of 4 days, 3 nights inpatient and 2 outpatient visits.  Each treatment period is seperated by 2 to 5 days.

     

    COMPENSATION: Up to $2,950

              

                         For more information about this research, please contact:

                         Kevin Fitzgerald: 651-724-5046 or prismresearchinc.com

  • Study 1404: Healthy Male and Female (of Non-Child Bearing Potential) Particpants

    Research Purpose:  Study 1404 is designed to evaluate two different formulations of an investigational drug being developed for the treatment of human rhinovirus. The investigational drug will be given orally to healthy participants two times: once in the form of a tablet and once in the form of a capsule. The following will be evaluated:

    • How much of the investigational drug gets into the blood when it is given as the tablet formulation verses the capsule formulation
    • The safety/tolerability of the investigational drug

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women are allowed to participate only if they are postmenopausal or surgically sterilized by hysterectomy, tubal ligation, or bilateral oophorectomy

    Age

    18-55 years

    Body Mass Index (BMI)

    18 and 30

    Weight

    Must weigh greater or equal to 110 pounds

    Tobacco/Nicotine Use

    • Must not use of tobacco/nicotine products more than 5 times/day in the 90 days before the study. 
    • Must be able and willing to abstain from tobacco/nicotine use 14 days before the start of the study until the final study visit. 

    Drug Testing

    Must test negative for drugs of abuse. 

    Substance Abuse History

    No history of drug or alcohol abuse within 2 years before the start of the study

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

    Restricted Medications

    • No chronic use of any prescription medications in the 90 days prior to the start of the study through the final study visit
    • No over-the-counter medications, supplements, or vitamins 7 days prior to the start of the stud through the final study visit.

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 2 weeks. 

    In-house Stays

    Participants will stay at Prism Clinical Research two times. 

    • Both in-house stays will last 2 ½ days (2 overnights)
    • There will be a 6 day washout period between the two in-house stays

    Study Visits

    The second inpatient stay is followed by one brief Study Visit 5 days later.

     

    Compensation: Up to $1270.00 for study particpation time.

  • Study 1317-Participants with varying degrees of kidney function

    RESEARCH PURPOSE:  To study the safety, absorption, and elimination of an investigational anticoagulant medication in people with reduced kidney function.

    BASIC PARTICIPANT QUALIFICATIONS:

    • Males and females 18-75 years old with less then normal kidney function but otherwise healthy and demographically matched healthy participants.
    • Cannot weigh more then 220 pounds.
    • Must test negative for HIV, Hepatitis B and C.
    • Cannot currently be using anticoagulants like Coumadin, warfarin, Heparin, etc.
    • Must have no significant history of blood or blood clotting disease or disorders.
    • Medications must be stable for 30 days prior to study start.

    STUDY LENGTH: One initial screening visit to determine study eligibility. One 4 night inpatient stay at the clinical research unit followed by 3 brief outpatient visits ( admit day -1, discharge day 4, visits days 5, 6 & 28)

    COMPENSATION: Up to $1500.00

     

     

     

Recruitment and Volunteer Demographics

Prism Clinical Research recognizes the need to continually grow our diverse volunteer database populations. Through a multi-faceted enrollment process that includes a dedicated recruitment department, collaborative physician partnerships, advertising and subject referral programs, Prism Clinical Research can deliver Phase I-II results in the following populations:

  • HIV

  • Hepatic

  • Renal (Pre-ESRD, ESRD)

  • Type 2 Diabetes

  • Obesity

  • Healthy Male/Female/Elderly

  • Gilbert’s subset

  • Rheumatoid Arthritis

  • Epilepsy

  • Multiple Sclerosis
  • GI (IBS & Crohn’s)

  • Celiac
  • COPD, Allergy and Asthma

  • High Cholesterol

  • Hypertensive

  • Alzheimer's Disease
  • Ophthalmology

  • Slow Metabolizers

  • Osteoporosis
  • Osteoarthritis
  • Lupus

Please provide us with your contact information (below) and will get back to you as soon as possible.

If you have a general question, check Volunteer FAQ for an answer. If you're unsure of who to contact, please visit the Contact Us page.

Cancel